Deep Learning Firms Accelerate Drug Discovery with AI
A new analysis identifies five deep learning startups leveraging AI to accelerate the drug discovery process. These companies focus on data analysis, drug design, and toxicity prediction.
Market research firm Roots Analysis has identified five startup companies leading the application of deep learning technology in drug discovery. The selection focused on companies established since 2019, highlighting their potential to transform the drug development pipeline using artificial intelligence (AI).
The analysis reviewed over 200 firms offering deep learning services and technologies for drug discovery and diagnostics. These companies specialize in analyzing large datasets, designing drugs, predicting toxicity, and identifying drug candidates.
The report emphasizes deep learning's role in overcoming challenges within drug discovery. AI can significantly enhance process efficiency and reduce costs. The sector has seen substantial startup activity recently, with 47% of deep learning companies established post-2015.
The identified companies include Cortex Discovery (Germany), Ensem Therapeutics (USA), Isomorphic Labs (an Alphabet subsidiary, UK), Merative (formerly IBM Watson Health, USA), and Sravathi AI (India). These firms represent the forefront of the industry and are expected to drive advancements in deep learning for medical applications.